Luye Pharma Group Ltd. (HKG:2186)

Luye Pharma Group Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	4,937	3,239	2,324	2,438	3,865
Short-Term Investments	62	1,272	1,247	387.86	109
Trading Asset Securities	1,504	1,596	1,974	2,684	1,432
Cash & Short-Term Investments	6,503	6,106	5,544	5,510	5,406
Cash Growth	6.50%	10.14%	0.62%	1.92%	39.33%
Accounts Receivable	2,780	2,355	1,784	1,765	1,553
Other Receivables	1,598	320.52	550.76	668.41	253.52
Receivables	4,378	2,675	2,334	2,434	1,807
Inventory	911.89	827.86	772.94	746.34	612.3
Prepaid Expenses	323.6	94.13	466.54	-	93.7
Restricted Cash	-	-	32	31.98	37.47
Other Current Assets	1,192	999.44	1,636	1,675	2,014
Total Current Assets	13,308	10,703	10,786	10,397	9,970
Property, Plant & Equipment	5,339	5,089	4,589	4,203	4,016
Long-Term Investments	2,492	1,968	1,114	582.2	71.46
Goodwill	1,012	1,042	1,003	985.41	1,057
Other Intangible Assets	5,464	4,805	4,448	4,080	3,765
Long-Term Deferred Tax Assets	163.58	144.59	113.95	133.11	114.74
Long-Term Deferred Charges	1,122	1,513	1,536	1,362	1,005
Other Long-Term Assets	710.96	226.1	658.43	839.37	631.68
Total Assets	29,612	25,491	24,250	22,582	20,631
Accounts Payable	689.3	767.19	559.94	570.89	485.26
Accrued Expenses	626.1	746.77	686.18	430.41	210.47
Short-Term Debt	5,118	4,568	4,723	4,740	5,415
Current Portion of Long-Term Debt	2,447	609.05	2,102	500.62	214.81
Current Portion of Leases	19.79	18.5	15.25	22.75	13.01
Current Income Taxes Payable	294.39	200.33	133.2	141.14	308.35
Current Unearned Revenue	188.26	156.55	72.83	70.99	131.19
Other Current Liabilities	1,386	1,071	1,195	853.54	455.97
Total Current Liabilities	10,769	8,138	9,487	7,330	7,234
Long-Term Debt	2,694	3,176	2,241	4,208	4,327
Long-Term Leases	42.17	52.15	23.24	19.21	11.73
Long-Term Unearned Revenue	130.56	172.22	384.44	209.39	185.66
Long-Term Deferred Tax Liabilities	36.48	47.26	56.03	57.87	74.32
Other Long-Term Liabilities	181.03	372.65	1,013	1,636	690.76
Total Liabilities	13,859	11,962	13,208	13,468	12,532
Common Stock	486.11	486.11	456.95	455.84	417.99
Additional Paid-In Capital	4,250	4,159	3,077	1,716	1,042
Retained Earnings	7,832	7,381	6,667	6,062	6,209
Treasury Stock	-	-	-279.56	-279.56	-279.56
Comprehensive Income & Other	1,587	505.21	254.46	534.04	501.52
Total Common Equity	14,155	12,531	10,176	8,488	7,891
Minority Interest	1,599	997.31	865.77	625.78	207.78
Shareholders' Equity	15,754	13,528	11,042	9,114	8,099
Total Liabilities & Equity	29,612	25,491	24,250	22,582	20,631
Total Debt	10,321	8,424	9,105	9,491	9,982
Net Cash (Debt)	-3,818	-2,318	-3,560	-3,980	-4,575
Net Cash Per Share	-1.01	-0.62	-1.02	-1.16	-1.43
Filing Date Shares Outstanding	3,762	3,762	3,550	3,541	3,183
Total Common Shares Outstanding	3,762	3,762	3,550	3,541	3,183
Working Capital	2,539	2,565	1,299	3,066	2,736
Book Value Per Share	3.76	3.33	2.87	2.40	2.48
Tangible Book Value	7,678	6,684	4,724	3,423	3,070
Tangible Book Value Per Share	2.04	1.78	1.33	0.97	0.96
Buildings	2,613	2,013	1,707	1,602	1,455
Machinery	4,119	3,636	3,408	3,031	2,718
Construction In Progress	884.73	1,381	1,081	832.93	864.86
Leasehold Improvements	59.49	54.98	43.93	40.26	25.4

Source: S&P Global Market Intelligence. Standard template. Financial Sources.